Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

A compound of Formula (Ia) or (Ib):

• with:
• n:
• 0,1
• m:
• 1,2,3,4
• Z:
• —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H,
• —PO4H2
• X:
• Naphthyl, Phenyl, Biphenyl, Indolyl (=2,3-benzopyrrolyl),
• Benzothiazolyl
• Y:
• Aryl, Alkylaryl, Cyclopentyl, Cyclohexyl, Cycloheptyl
• Che-
• 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid
• lator:
• (=DOTA),
• N,N″-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-
• N,N″-diacetic acid (=HBED-CC),
• 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA),
• 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid
• (NODAGA),
• 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-
• yl)pentanedioic acid
• (DOTAGA),
• 1,4,7-triazacyclononane phosphinic acid (TRAP),
• 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic
• acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO),
• 3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-
• triacetic acid (=PCTA),
• N′-{5-[Acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-
• aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-
• hydroxysuccinamide (DFO),
• Diethylenetriaminepentaacetic acid (DTPA)
• Trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA)
• 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A)
• p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA)
• 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M)
• 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B)
• 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA)